Ipca Laboratories Ltd.
Snapshot View

View in App

Prices View details >>

776.75 -4.10 ▼-0.5%

21 March 2023, 04:01:00 PM
Volume: 3,293

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ipca.com
Market Cap 19,759.75 Cr.
Enterprise Value(EV) 19,338.72 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 20.69 Trailing Twelve Months Ending 2022-12
Price-Earning Ratio (PE) 37.64 Trailing Twelve Months Ending 2022-12
Industry PE 31.71 Trailing Twelve Months Ending 2022-12
Book Value / Share 232.67 Trailing Twelve Months Ending 2022-12
Price to Book Value 3.35 Calculated using Price: 778.85
Dividend Yield 0.51 Period Ending 2022-03
No. of Shares Subscribed 25.37 Cr. 253,704,218 Shares
FaceValue 1
Company Profile
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. Ipca Laboratories is one of the largest suppliers of these APIs worldwide with manufacturing leadership in many APIs globally. It has various APIs and formulations manufacturing facility across the globe. The company has leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.53%
1 Week
-0.62%
1 Month
-4.58%
3 Month
-13.37%
6 Month
-10.36%
1 Year
-22.60%
2 Year
-15.57%
5 Year
+134.37%
10 Year
+198.12%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 27.22 12.43 4.31 8.60 9.47 15.28 18.15 27.63 17.87
Return on Capital Employed (%) 27.92 13.78 4.82 9.44 9.94 16.53 19.92 30.92 20.41
Return on Assets (%) 16.19 7.38 2.50 5.17 6.03 10.25 12.47 20.29 13.30

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 1,960 2,208 2,259 2,455 2,689 3,122 3,627 4,702 5,492 5,778
Non Curr. Liab. 459 700 663 548 419 313 290 190 602 652
Curr. Liab. 791 904 970 956 1,008 1,098 1,326 1,161 1,466 1,385
Minority Int. 16 14 15 77 81
Equity & Liab. 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 7,896
Non Curr. Assets 1,609 2,198 2,270 2,218 2,170 2,171 2,402 2,629 3,180 3,342
Curr. Assets 1,601 1,614 1,622 1,742 1,945 2,378 2,856 3,437 4,457 4,554
Misc. Exp. not W/O
Total Assets 3,211 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 7,896

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-12 Rs. Cr. TTM
Net Sales 3,282 3,144 2,867 3,156 3,258 3,746 4,619 5,395 5,797 6,022
Other Income 52 59 41 55 58 75 87 129 122 104
Total Income 3,334 3,203 2,908 3,211 3,316 3,820 4,706 5,524 5,918 6,126
Total Expenditure -2,570 -2,630 -2,593 -2,741 -2,816 -3,067 -3,729 -3,914 -4,539 -5,057
PBIDT 764 573 314 470 500 753 977 1,610 1,379 1,069
Interest -30 -32 -35 -27 -28 -22 -20 -12 -11 -30
Depreciation -103 -180 -163 -173 -178 -182 -211 -209 -232 -253
Taxation -152 -102 -20 -68 -51 -104 -135 -240 -225 -234
Exceptional Items
PAT 478 259 96 203 244 444 611 1,149 911 552
Minority Interest 3 3 -1 -6 -8
Share Associate 0 -5 -3 -8 -4 -2 -8 -8 -21 -19
Other Related Items
Consolidated Net Profit 479 254 93 195 239 446 606 1,140 884 525
Adjusted EPS 19 10 4 8 9 18 24 45 35 21

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 389 522 468 709 282 341 501 570 1,090 856
Cash Fr. Inv. -260 -369 -689 -218 -149 -135 -165 -510 -521 -855
Cash Fr. Finan. -83 -136 251 -462 -159 -130 -183 -137 -306 427
Net Change 46 17 29 29 -26 75 153 -76 264 428
Cash & Cash Eqvt 57 74 104 169 143 218 371 295 559 991

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 46.29 46.29 46.29 46.29 46.29 46.29 46.29 46.29 46.29
Public 53.71 53.71 53.71 53.71 53.71 53.71 53.71 53.71 53.71
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Mon, 20 Mar 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the details of lost share certificate(s) for which stop transfer has been marked by the Registrar:
Mon, 06 Mar 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyIPCA LABORATORIES LTD.
2CIN NO.L24239MH1949PLC007837
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 372.44
4Highest Credit Rating during the previous FY AA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES



Name of the Company Secretary: Harish P Kamath
Designation: Corporate Counsel and Company Secretary
EmailId: harish.kamath@ipca.com
Name of the Chief Financial Officer: Ajit Kumar Jain
Designation: Joint Managing Director
EmailId: ajit.jain@ipca.com

Date: 06/03/2023

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Tue, 28 Feb 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication regarding dispatch of Postal Ballot Notice and E-voting Details for Postal Ballot

Technical Scans View Details >>

Mon, 20 Mar 2023
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Month Low Close Below Last Month Low
High Decrease in 1 Month High Decrease in 1 Month
High Decrease in 3 Months High Decrease in 3 Months
High Increase in 5 Years High Increase in 5 Years

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 230,636.07 956.20 -0.5%
Divi's Laboratories Ltd. 74,303.33 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. 73,967.90 4,419.30 -0.5%
Cipla Ltd. 70,000.14 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. 61,905.77 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. 51,514.78 1,518.00 -0.3%
Zydus Lifesciences Ltd. 48,165.73 477.95 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 54.76 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-12 31.06 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 20.25 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-12 26.53 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 80.95 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 61.90 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 23.34 477.95 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.17 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-12 5.98 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.35 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-12 3.08 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.04 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.07 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-12 2.79 477.95 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 0.04 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 477.95 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 13.10 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 477.95 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 13.10 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 477.95 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 477.95 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 956.20 -0.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 2,773.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,419.30 -0.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 862.70 -0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,272.60 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,518.00 -0.3%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 477.95 +0.4%

FAQ's On Ipca Laboratories Ltd.

What is Ipca Laboratories share price?
Can I buy Ipca Laboratories shares now?
What is the Dividend Yield of Ipca Laboratories?
What is the Market Cap of Ipca Laboratories?
What are the key metrics to analyse Ipca Laboratories?
What is the 52 Week High and Low of Ipca Laboratories?
What is the trend of Ipca Laboratories share price?